{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:54:23Z","timestamp":1777859663076,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2012,7,13]],"date-time":"2012-07-13T00:00:00Z","timestamp":1342137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Evaluate the impact of replacing hydroxyethyl starch (HES) 670\/0.75 with lower molecular weight HES 130\/0.4 on albumin utilization in cardiac surgery, as well as any impact on renal function and bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A pre- and postimplementation, retrospective analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>Community, not-for-profit, tertiary medical center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants:<\/jats:title>\n                    <jats:p>One hundred forty-six patients undergoing nonemergent cardiac bypass graft and cardiac valve surgeries after exclusion for documented anemia, malignancy, coagulation disorder, end-stage renal disease, or personal objection to receiving blood products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention:<\/jats:title>\n                    <jats:p>HES 130\/0.4 utilization instead of HES 670\/0.75 for volume expansion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results:<\/jats:title>\n                    <jats:p>Patients were less likely to be administered albumin intraoperatively (odds ratio [OR] 0.16, confidence interval [CI] 0.08-0.35, P &lt; .001). When albumin was utilized, intraoperative amounts were similar (mean \u00b1 standard deviation [SD]: 36.1 \u00b1 17.1 g vs 43.8 \u00b1 15.5 g, P = .16). Patients were more likely to receive an intraoperative HES product after the formulary change (OR 11.1, CI 4.4-27.6, P &lt; .001) as well as larger volumes (mean \u00b1 SD: 743 \u00b1 544 mL vs 500 \u00b1 0 mL, P = .01). No differences were detected in mean baseline-to-discharge changes in serum creatinine or in postoperative urine output, nor were there differences in clinically significant bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Change to a lower molecular weight HES decreased intraoperative albumin utilization and increased HES utilization with no detected difference in renal function or bleeding complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190012451931","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T03:52:59Z","timestamp":1342237979000},"page":"606-610","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Albumin Utilization in Cardiac Surgery After Transition to Hydroxyethyl Starch 130\/0.4"],"prefix":"10.1177","volume":"25","author":[{"given":"David B.","family":"Romerill","sequence":"first","affiliation":[{"name":"Pharmacy Practice, University of New England College of Pharmacy, Portland, ME, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Y.","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Massachussetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon E.","family":"Brodeur","sequence":"additional","affiliation":[{"name":"Critical Care, Pharmacy Department, Eastern Maine Medical Center, Bangor, ME, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Moellentin","sequence":"additional","affiliation":[{"name":"Pharmacy Practice, Husson University School of Pharmacy, Bangor, ME, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,7,13]]},"reference":[{"key":"bibr1-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e32830dd073"},{"key":"bibr2-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1007\/s11248-004-6481-5"},{"key":"bibr3-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004269646"},{"key":"bibr4-0897190012451931","unstructured":"Hespan\n                      \u00ae\n                      (6% hetastarch in 0.9% sodium chloride injection) [package insert]. Irvine, CA: B. Braun Medical, Inc; 2003. Available at http:\/\/www.bbraunusa.com\/search\/interim.asp. Accessed July 12, 2011."},{"key":"bibr5-0897190012451931","unstructured":"Hextend\n                      \u00ae\n                      (6% hetastarch in lactated electrolyte injection) [package insert]. Lake Forest, IL: Hospira, Inc. September 2008. Available at http:\/\/www.hospira.com\/Products\/Hextend.aspx. Accessed July 12, 2011."},{"key":"bibr6-0897190012451931","unstructured":"Voluven\n                      \u00ae\n                      (6% hydroxyethyl starch 130\/0.4 in 0.9% sodium chloride injection) [package insert]. Lake Forest, IL: Hospira, Inc; 2007. Available at http:\/\/products\/hospira.com\/search\/productDetails?listnumber=Voluven&category=Drugs&page=Drug&sort=ndc&order=asc. Accessed July 12, 2011."},{"key":"bibr7-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-004-0237-3"},{"key":"bibr8-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1017\/S0265021506000639"},{"key":"bibr9-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00186.x"},{"key":"bibr10-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707163170306"},{"key":"bibr11-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(96)01071-5"},{"key":"bibr12-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-200004000-00006"},{"key":"bibr13-0897190012451931","unstructured":"Approval memorandum - Voluven. December 20, 2007: U.S. Food and Drug Administration, Center for Drug Evaluation; 2007."},{"key":"bibr14-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200606000-00018"},{"key":"bibr15-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-200302000-00056"},{"key":"bibr16-0897190012451931","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544070-00002"},{"key":"bibr17-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1186\/cc8920"},{"key":"bibr18-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-2144-x"},{"key":"bibr19-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e31817e6eac"},{"key":"bibr20-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181f3e08c"},{"key":"bibr21-0897190012451931","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-010-2117-9"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190012451931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190012451931","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190012451931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:35:14Z","timestamp":1777509314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190012451931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,13]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1177\/0897190012451931"],"URL":"https:\/\/doi.org\/10.1177\/0897190012451931","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,13]]}}}